InnoCan Pharma Corporation (CSE:INNO)

InnoCan Pharma Statistics

Total Valuation

InnoCan Pharma has a market cap or net worth of CAD 116.58 million. The enterprise value is 111.98 million.

Market Cap	116.58M
Enterprise Value	111.98M

Important Dates

The next estimated earnings date is Thursday, November 20, 2025.

Earnings Date	Nov 20, 2025
Ex-Dividend Date	n/a

Share Statistics

InnoCan Pharma has 6.04 million shares outstanding. The number of shares has increased by 7.00% in one year.

Current Share Class	6.04M
Shares Outstanding	6.04M
Shares Change (YoY)	+7.00%
Shares Change (QoQ)	+0.66%
Owned by Insiders (%)	2.54%
Owned by Institutions (%)	0.13%
Float	5.12M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.97
PB Ratio	12.78
P/TBV Ratio	20.32
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 233.24, with an EV/FCF ratio of -175.06.

EV / Earnings	-52.10
EV / Sales	2.85
EV / EBITDA	233.24
EV / EBIT	258.18
EV / FCF	-175.06

Financial Position

The company has a current ratio of 3.70, with a Debt / Equity ratio of 0.21.

Current Ratio	3.70
Quick Ratio	2.70
Debt / Equity	0.21
Debt / EBITDA	3.97
Debt / FCF	-2.98
Interest Coverage	26.50

Financial Efficiency

Return on equity (ROE) is -4.84% and return on invested capital (ROIC) is 2.81%.

Return on Equity (ROE)	-4.84%
Return on Assets (ROA)	2.01%
Return on Invested Capital (ROIC)	2.81%
Return on Capital Employed (ROCE)	3.93%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	2.92
Inventory Turnover	1.26

Taxes

In the past 12 months, InnoCan Pharma has paid 1.28 million in taxes.

Income Tax	1.28M
Effective Tax Rate	148.97%

Stock Price Statistics

The stock price has increased by +41.47% in the last 52 weeks. The beta is -0.43, so InnoCan Pharma's price volatility has been lower than the market average.

Beta (5Y)	-0.43
52-Week Price Change	+41.47%
50-Day Moving Average	14.35
200-Day Moving Average	12.83
Relative Strength Index (RSI)	63.68
Average Volume (20 Days)	2,955

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, InnoCan Pharma had revenue of CAD 39.32 million and -2.15 million in losses. Loss per share was -0.49.

Revenue	39.32M
Gross Profit	34.78M
Operating Income	433,707
Pretax Income	857,868
Net Income	-2.15M
EBITDA	480,079
EBIT	433,707
Loss Per Share	-0.49

Balance Sheet

The company has 9.89 million in cash and 1.91 million in debt, giving a net cash position of 7.99 million or 1.32 per share.

Cash & Cash Equivalents	9.89M
Total Debt	1.91M
Net Cash	7.99M
Net Cash Per Share	1.32
Equity (Book Value)	9.12M
Book Value Per Share	1.28
Working Capital	10.89M

Cash Flow

In the last 12 months, operating cash flow was -617,829 and capital expenditures -21,822, giving a free cash flow of -639,651.

Operating Cash Flow	-617,829
Capital Expenditures	-21,822
Free Cash Flow	-639,651
FCF Per Share	-0.11

Margins

Gross margin is 88.45%, with operating and profit margins of 1.10% and -5.47%.

Gross Margin	88.45%
Operating Margin	1.10%
Pretax Margin	2.18%
Profit Margin	-5.47%
EBITDA Margin	1.22%
EBIT Margin	1.10%
FCF Margin	n/a

Dividends & Yields

InnoCan Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-7.00%
Shareholder Yield	-7.00%
Earnings Yield	-1.84%
FCF Yield	-0.55%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on September 5, 2025. It was a reverse split with a ratio of 0.015384615.

Last Split Date	Sep 5, 2025
Split Type	Reverse
Split Ratio	0.015384615

Scores

InnoCan Pharma has an Altman Z-Score of 4.9 and a Piotroski F-Score of 3.

Altman Z-Score	4.9
Piotroski F-Score	3